| New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes RS Janssen, GA Satten, SL Stramer, BD Rawal, TR O'Brien, BJ Weiblen, ... Jama 280 (1), 42-48, 1998 | 872 | 1998 |
| Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population RY Dodd, EP Notari IV, SL Stramer Transfusion 42 (8), 975-979, 2002 | 863 | 2002 |
| Transmission of West Nile virus through blood transfusion in the United States in 2002 LN Pealer, AA Marfin, LR Petersen, RS Lanciotti, PL Page, SL Stramer, ... New England Journal of Medicine 349 (13), 1236-1245, 2003 | 816 | 2003 |
| Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid–amplification testing SL Stramer, SA Glynn, SH Kleinman, DM Strong, S Caglioti, DJ Wright, ... New England Journal of Medicine 351 (8), 760-768, 2004 | 697 | 2004 |
| A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors MP Busch, SA Glynn, SL Stramer, DM Strong, S Caglioti, DJ Wright, ... Transfusion 45 (2), 254-264, 2005 | 578 | 2005 |
| Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis AL Greninger, SN Naccache, S Federman, G Yu, P Mbala, V Bres, ... Genome medicine 7, 1-13, 2015 | 573 | 2015 |
| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity SV Bardina, P Bunduc, S Tripathi, J Duehr, JJ Frere, JA Brown, ... Science 356 (6334), 175-180, 2017 | 569 | 2017 |
| Emerging infectious disease agents and their potential threat to transfusion safety SL Stramer, FB Hollinger, LM Katz, S Kleinman, PS Metzel, KR Gregory, ... Transfusion 49, 1S-29S, 2009 | 523 | 2009 |
| Nucleic acid testing to detect HBV infection in blood donors SL Stramer, U Wend, D Candotti, GA Foster, FB Hollinger, RY Dodd, ... New England Journal of Medicine 364 (3), 236-247, 2011 | 391 | 2011 |
| Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic … S Zou, KA Dorsey, EP Notari, GA Foster, DE Krysztof, F Musavi, RY Dodd, ... Transfusion 50 (7), 1495-1504, 2010 | 382 | 2010 |
| The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations BR Jackson, MP Busch, SL Stramer, JP AuBuchon Transfusion 43 (6), 721-729, 2003 | 357 | 2003 |
| Unifying the spatial epidemiology and molecular evolution of emerging epidemics OG Pybus, MA Suchard, P Lemey, FJ Bernardin, A Rambaut, ... Proceedings of the national academy of sciences 109 (37), 15066-15071, 2012 | 285 | 2012 |
| International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 WK Roth, MP Busch, A Schuller, S Ismay, A Cheng, CR Seed, ... Vox Sanguinis 102 (1), 82-90, 2012 | 284 | 2012 |
| Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man JK Lim, A Lisco, DH McDermott, L Huynh, JM Ward, B Johnson, ... PLoS pathogens 5 (2), e1000321, 2009 | 268 | 2009 |
| Test performance evaluation of SARS-CoV-2 serological assays JD Whitman, J Hiatt, CT Mowery, BR Shy, R Yu, TN Yamamoto, U Rathore, ... Nature biotechnology 38 (10), 1174, 2020 | 264 | 2020 |
| Transfusion-transmitted infectious diseases JP Allain, SL Stramer, ABF Carneiro-Proietti, ML Martins, SNL Da Silva, ... Biologicals 37 (2), 71-77, 2009 | 254 | 2009 |
| West Nile virus among blood donors in the United States, 2003 and 2004 SL Stramer, CT Fang, GA Foster, AG Wagner, JP Brodsky, RY Dodd New England Journal of Medicine 353 (5), 451-459, 2005 | 254 | 2005 |
| Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis KR Tan, AJ Magill, ME Parise, PM Arguin The American journal of tropical medicine and hygiene 84 (4), 517, 2011 | 250 | 2011 |
| Magnitude and kinetics of anti–severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity KL Lynch, JD Whitman, NP Lacanienta, EW Beckerdite, SA Kastner, ... Clinical Infectious Diseases 72 (2), 301-308, 2021 | 248 | 2021 |
| Evaluation of SARS-CoV-2 serology assays reveals a range of test performance JD Whitman, J Hiatt, CT Mowery, BR Shy, R Yu, TN Yamamoto, U Rathore, ... Nature biotechnology 38 (10), 1174-1183, 2020 | 245 | 2020 |
